Literature DB >> 20616339

Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.

Leah N Cueni1, Ivan Hegyi, Jay W Shin, Andrea Albinger-Hegyi, Silke Gruber, Rainer Kunstfeld, Holger Moch, Michael Detmar.   

Abstract

The membrane glycoprotein podoplanin is expressed by several types of human cancers and might be associated with their malignant progression. Its exact biological function and molecular targets are unclear, however. Here, we assessed the relevance of tumor cell expression of podoplanin in cancer metastasis to lymph nodes, using a human MCF7 breast carcinoma xenograft model. We found that podoplanin expression promoted tumor cell motility in vitro and, unexpectedly, increased tumor lymphangiogenesis and metastasis to regional lymph nodes in vivo, without promoting primary tumor growth. Importantly, high cancer cell expression levels of podoplanin correlated with lymph node metastasis and reduced survival times in a large cohort of 252 oral squamous cell carcinoma patients. Based on comparative transcriptional profiling of tumor xenografts, we identified endothelin-1, villin-1, and tenascin-C as potential mediators of podoplanin-induced tumor lymphangiogenesis and metastasis. These unexpected findings identify a novel mechanism of tumor lymphangiogenesis and metastasis induced by cancer cell expression of podoplanin, suggesting that reagents designed to interfere with podoplanin function might be developed as therapeutics for patients with advanced cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616339      PMCID: PMC2913355          DOI: 10.2353/ajpath.2010.090703

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Ectopic expression of PA2.26 antigen in epidermal keratinocytes leads to destabilization of adherens junctions and malignant progression.

Authors:  F G Scholl; C Gamallo; M Quintanilla
Journal:  Lab Invest       Date:  2000-11       Impact factor: 5.662

2.  Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression.

Authors:  E Ioachim; A Charchanti; E Briasoulis; V Karavasilis; H Tsanou; D L Arvanitis; N J Agnantis; N Pavlidis
Journal:  Eur J Cancer       Date:  2002-12       Impact factor: 9.162

Review 3.  Changing concepts in the surgical management of the cervical node metastasis.

Authors:  Alfio Ferlito; Alessandra Rinaldo; K Thomas Robbins; C René Leemans; Jatin P Shah; Ashok R Shaha; Peter E Andersen; Luiz P Kowalski; Phillip K Pellitteri; Gary L Clayman; Simon N Rogers; Jesus E Medina; Robert M Byers
Journal:  Oral Oncol       Date:  2003-07       Impact factor: 5.337

4.  T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth.

Authors:  Maria I Ramirez; Guetchyn Millien; Anne Hinds; YuXia Cao; David C Seldin; Mary C Williams
Journal:  Dev Biol       Date:  2003-04-01       Impact factor: 3.582

5.  PANTHER: a library of protein families and subfamilies indexed by function.

Authors:  Paul D Thomas; Michael J Campbell; Anish Kejariwal; Huaiyu Mi; Brian Karlak; Robin Daverman; Karen Diemer; Anushya Muruganujan; Apurva Narechania
Journal:  Genome Res       Date:  2003-09       Impact factor: 9.043

6.  Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma.

Authors:  K Emoto; Y Yamada; H Sawada; H Fujimoto; M Ueno; T Takayama; K Kamada; A Naito; S Hirao; Y Nakajima
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

7.  Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.

Authors:  Hidetoshi Kawaguchi; Adel K El-Naggar; Vali Papadimitrakopoulou; Hening Ren; You-Hong Fan; Lei Feng; J Jack Lee; Edward Kim; Waun Ki Hong; Scott M Lippman; Li Mao
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

8.  T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema.

Authors:  Vivien Schacht; Maria I Ramirez; Young-Kwon Hong; Satoshi Hirakawa; Dian Feng; Natasha Harvey; Mary Williams; Ann M Dvorak; Harold F Dvorak; Guillermo Oliver; Michael Detmar
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

9.  A role for endothelin-2 and its receptors in breast tumor cell invasion.

Authors:  Matthew J Grimshaw; Thorsten Hagemann; Ayse Ayhan; Cheryl E Gillett; Claudia Binder; Frances R Balkwill
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

10.  Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors.

Authors:  Yukinari Kato; Naoya Fujita; Akiko Kunita; Shigeo Sato; Mika Kaneko; Motoki Osawa; Takashi Tsuruo
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

View more
  50 in total

1.  Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival.

Authors:  Juan Carlos de Vicente; Tania Rodríguez Santamarta; Juan Pablo Rodrigo; Juana María García-Pedrero; Eva Allonca; Verónica Blanco-Lorenzo
Journal:  Virchows Arch       Date:  2015-03-01       Impact factor: 4.064

2.  Tumor vascularization and clinicopathologic parameters as prognostic factors in merkel cell carcinoma.

Authors:  A Bob; F Nielen; J Krediet; J Schmitter; D Freundt; D Terhorst; J Röwert-Huber; J Kanitakis; E Stockfleth; Ch Ulrich; M Weichenthal; F Egberts; B Lange-Asschenfeldt
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-21       Impact factor: 4.553

Review 3.  Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity.

Authors:  Melody A Swartz; Amanda W Lund
Journal:  Nat Rev Cancer       Date:  2012-02-24       Impact factor: 60.716

Review 4.  Podoplanin: a novel regulator of tumor invasion and metastasis.

Authors:  Qi Dang; Jie Liu; Juan Li; Yuping Sun
Journal:  Med Oncol       Date:  2014-08-21       Impact factor: 3.064

5.  Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.

Authors:  Wen-Yu Chuang; Yu-Sun Chang; Yin-Kai Chao; Chi-Ju Yeh; Shir-Hwa Ueng; Chiu-Yueh Chang; Yun-Hen Liu; Chen-Kan Tseng; Hsien-Kun Chang; Yung-Liang Wan; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.

Authors:  Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina; Tohru Ikeda
Journal:  Pathol Oncol Res       Date:  2013-11-28       Impact factor: 3.201

7.  Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer.

Authors:  Agnes Assao; Suely Nonogaki; José Roberto Pereira Lauris; André Lopes Carvalho; Clóvis Antônio Lopes Pinto; Fernando Augusto Soares; Luiz Paulo Kowalski; Denise Tostes Oliveira
Journal:  Clin Oral Investig       Date:  2016-09-14       Impact factor: 3.573

8.  Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.

Authors:  Esak Lee; Jacob E Koskimaki; Niranjan B Pandey; Aleksander S Popel
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

9.  Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.

Authors:  Francesca Spinella; Valentina Caprara; Valeriana Di Castro; Laura Rosanò; Roberta Cianfrocca; Pier Giorgio Natali; Anna Bagnato
Journal:  J Mol Med (Berl)       Date:  2012-09-11       Impact factor: 4.599

Review 10.  Podoplanin - a small glycoprotein with many faces.

Authors:  Maciej Ugorski; Piotr Dziegiel; Jaroslaw Suchanski
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.